FDA Watch

 

Are Clinical Trial Participants Really That Diverse?

February 15, 2017
Are Clinical Trial Participants Really That Diverse?

The FDA this week released its Drug Trials Snapshots Summary Report, a document that looks at the diversity of the participants in trials for new drugs that were approved last year and in 2015. There’s a lot to be excited about. For example, women accounted for 48% of Continue Reading →

Trump and the Undermining of the FDA

February 1, 2017
Trump and the Undermining of the FDA

President Trump has been making policy decisions that directly impact health care. Most of them are not good for patients.

What Happens When The FDA Is Addicted to the Drug Industry?

December 8, 2016
What Happens When The FDA Is Addicted to the Drug Industry?

With the FDA receiving the vast majority of its funding to regulate drugs from that very industry, that’s a dangerous conflict of interest that puts everyone’s health at risk.

Time for the FDA to Get Tough on Off-Label Drug Promotion

November 2, 2016
Time for the FDA to Get Tough on Off-Label Drug Promotion

Pharmaceutical companies are getting bolder with pushing off-label drug use to doctors, but will an upcoming meeting embolden the FDA to get tougher?

The Importance of Prescription Drug Take-Back Day

October 19, 2016
The Importance of Prescription Drug Take-Back Day

The next National Prescription Drug Take-Back Day is Oct. 19. Find out why it is important to get rid of unused drugs and how to dispose of them properly.

FDA Needs to Go Further in Curbing E-Cig Use by Teens

October 5, 2016
FDA Needs to Go Further in Curbing E-Cig Use by Teens

The FDA has new powers to regulate e-cigarettes. The agency should use them to restrict advertising to teens and ban flavored vaping liquid that appeals directly to young people.

When an FDA Drug Approval is a Bad Decision

September 21, 2016
When companies sell vape juice flavors like Cotton Candy or Yummy Gummy, they aren't marketing to adults. The FDA needs to do more to protect teens. Read more >>

The FDA’s approval this week of a new drug with weak trial data for muscular dystrophy was based on public pressure rather than sound science.